EmmettVSchmidtMD
Pediatrics • Gwynedd, PAVice President; Clinical Research - Oncology; Merck and Co.; Inc
Dr. Schmidt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
351 North Sumneytown Pike
Mailstop UG-4D012
Gwynedd, PA 19454Phone+1 267-305-3326
Education & Training
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1981 - 1984
Duke University School of MedicineClass of 1981
Certifications & Licensure
MA State Medical License 1984 - 2017- American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 99 citationsLenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor
The Lancet. Oncology. 2021-07-01 - 5 citationsIndependent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.Linda Z. Sun, Cai Wu, Xiaoyun Li, Cong Chen, Emmett V. Schmidt
Contemporary Clinical Trials. 2021-05-15 - 53 citationsEntinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez
Clinical Cancer Research. 2021-02-15
Journal Articles
- Developing Combination Strategies Using PD-1 Checkpoint Inhibitors to Treat CancerEmmett Schmidt, MD, Seminars in Immunopathology
Grant Support
- Evolutionary LEAD Optimization For Immunotherapy Of Marburg &Ebola VirusesNational Institute Of Allergy And Infectious Diseases2006–2009
- Functions Of Cyclin D1 In Breast CancerNational Cancer Institute1997–2007
- Genes Regulated By C MYCNational Cancer Institute2000–2004
- Creation Of Animal Models For Human Breast CancerNational Cancer Institute2000–2002
- Hepatitis C Transgenic Mice As Model Of Liver InjuryNational Institute Of Allergy And Infectious Diseases1998–2000
- Genes Regulated By C-MYCNational Cancer Institute1994–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
